Introduction Although relevant for precision pharmacovigilance, there are conflicting data on whether former preterm birth is associated with QT c-Bazett prolongation in later life. Methods To explore QT c-Bazett interval differences between former preterm and/or extremely low birth weight (ELBW) cases and term-born controls in adolescence and young adulthood, we analyzed pooled individual data after a structured search on published cohorts. To test the absence of a QT c-Bazett difference, a non-inferiority approach was applied (one-sided, upper limit of the 95% confidence interval [CI] mean QT c-Bazett difference, 5 and 10 ms). We also investigated the impact of characteristics, either perinatal or at assessment, on QT c-Bazett in the full dataset (cases and controls). Data were reported as median and range. Results The pooled dataset contained 164 former preterm and/or ELBW (cases) and 140 controls born full-term from three studies. The median QT c-Bazett intervals were 409 (335–490) and 410 (318–480) ms in cases and controls. The mean QT c-Bazett difference was 1 ms, with an upper 95% CI of 6 ms ( p > 0.05 and p < 0.01 for 5 and 10 ms, respectively). In the full dataset, females had a significantly longer QT c-Bazett than males (415 vs. 401 ms; p < 0.0001). Conclusions QT c-Bazett intervals are not significantly different between former preterm and/or ELBW cases and term-born controls, and we rejected a potential prolongation > 10 ms in cases. When prescribing QTc-prolonging drugs, pharmacovigilance practices in this subpopulation should be similar to the general public (NCT05243537). Supplementary Information The online version contains supplementary material available at 10.1007/s40264-023-01335-y.

No abstract

The aim of the research. To determine the predictors of a decrease in the quality of life of patients with the senile asthenia syndrome and paroxysmal atrial fibrillation. Material and methods. A total of 45 patients aged over 65 with paroxysmal atrial fi brillation (AF) and senile asthenia (SA) syndrome were selected and constituted the main group. A control group of 43 apparently healthy individuals was formed as well. Th e search for predictors of a decrease in the quality of life (QoL) in patients with SA syndrome and paroxysmal AF was carried out based on standardised laboratory and instrumental studies. Results. Th e QoL of patients with SA syndrome and paroxysmal AF is declined according to indicators relevant for apparently healthy individuals comparable in age and gender characteristics. In comparison to men, women have demonstrated a decrease of the QoL according to three of the four scales of physical health: PF, RP, GH, and on two scales of psychosocial health: RE and MH. In the age group of subject aged over 75, mainly the indicators of physical status – PF, RP and GH – were reduced. With GFR lowering to less than 60 ml/min, there is predominantly a decline in the physical aspect of the QoL as well as a decrease in vital activity. Deterioration in the QoL was determined on two scales of the physical aspect of health – PF and RP – against the background of HR higher than 80 bpm, while no changes in the psychosocial aspect were diagnosed. Conclusion. The quality of life of patients with the senile asthenia syndrome and paroxysmal AF has the worst values on absolutely all scales of the physical aspect of health, whereas the psychosocial sphere is less involved and only vital activity and role-based emotional functioning are reduced. Predictors of QoL deterioration in patients with the SA syndrome and paroxysmal AF are: the age of 75 or older, the female gender, a decrease in GFR down to 60 ml/min and an increase in the heart rate to over 80 bpm. Thus, rational nephroprotective therapy and heart rate control contribute to the improvement in the quality of life of patients with the SA syndrome and paroxysmal AF.

Background. Patients with COVID-19 and senile asthenia syndrome (SA) are characterized by extremely high comorbidity, heterogeneity, atypical course of the disease, and large number of complications. We carried out a comprehensive assessment of the quality of life (QOL) in patients with COVID-19 and SA considering the high prevalence of this category of patients and the absence of such studies.Material and Methods. Group 1 included 37 patients with SA and history of COVID-19 three months after discharge from the hospital. Group 2 included 35 patients with CA and history of COVID-19 six months later. Control group comprised 34 patients with SA aged over 65 years who did not have COVID-19. The assessment of QOL was carried out according to the SF-36 questionnaire.Results. There was a decrease in absolutely all indicators of physical and psychosocial aspects of health three months after discharge from the hospital. There was a more pronounced decrease in the scales of physical functioning (PF), role-physical functioning (RP), general health (GH), and mental health (MH) after six months. There was a lower QOL in female population according to most scales (PF, RP, GH, MH, and role-emotional functioning (RE)) regardless of the time from the moment of discharge from the hospital, and a higher incidence of depression compared to men.Conclusions. All QOL indicators of patients with SA and history of COVID-19 decreased within the first three months after discharge from the hospital. At the same time, after six months, a decrease in physical status was most pronounced, while the indicators of mental sphere reduced only according to the MH scale. At three and six months after discharge, the quality of life in the male population was higher than in the female population according to the same evaluation scales (PF, RP, GH, MH, and RE). The best indicators of pain scale in men were characteristic only for the first group of patients, whereas there was no statistically significant difference according to the social functioning and MH data. There was a higher incidence of depression in the female population, while the prevalence of anxiety was higher at three months after discharge than after six months.